Vabysmo Is Bright Spot For Roche In Bumpy Q3

Anticipation Grows On Alzheimer’s Result

 
• By Andrew McConaghie

Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.  

Roche_White_Logo
Roche got a big boost from its COVID-19 therapies last year, but does not expect further sales spikes, despite the unpredictability of SARS-CoV2. • Source: Shutterstock

More from Earnings

More from Business